Gastrointestinal Implants - An Overview

Sahoo Suryakant, Golab Alexander, Rossi Francesco
Email: {suryakant.sahoo, alexander.golab, rossi.francesco}@epfl.ch

***Abstract*—Gastrointestinal implants are key tools for diagnosing, monitoring, and treating digestive disorders. They must operate in a complex physiological environment, requiring biocompatible, miniaturized devices capable of sensing mechanical, chemical, biological, and electrical signals. This paper provides an overview of GI anatomy and associated pathologies, followed by a survey of ingestible electronic pills, covering sensing modalities, integrated circuits, communication schemes, power strategies, and packaging constraints. We also examine implantable neuromodulation systems, including gastric electrical stimulators and vagal-blocking devices, discussing their architectures, clinical applications, and therapeutic outcomes. These technologies highlight rapid progress in gut-focused bioelectronics and their potential to deliver real-time, patient-specific insights beyond traditional therapies.**

I. Overview [1]

Gastrointestinal (GI) implants have emerged as a promising class of medical devices for diagnosis, monitoring, and treatment of gut disorders
involving motility, secretion, and digestion. Their development is driven by the high prevalence of conditions such as gastroparesis, functional dyspepsia, obesity, constipation, and intestinal dysmotility, for which pharmacological treatments offer limited and inconsistent results. Nonetheless, the GI tract presents a uniquely challenging environment for device design, as it spans across multiple organs, each with different transit times, pH levels, and biomechanical properties, governed by complex interactions between smooth muscles, interstitial cells, the enteric nervous system (ENS), and autonomic neural pathways. GI implants must thus be designed to be biocompatible, robust, miniaturized, and capable of interacting with such heterogeneous physiological conditions.

A. Gastrointestinal Organs

In order to efficiently design such devices, we must first understand the targeted area. Structurally, the gastrointestinal tract is composed of four major regions: the esophagus, stomach, small and large intestines (Fig. 1).



Fig. 1. Anatomical overview of the major gastrointestinal organs: esophagus, stomach, small and large intestine

After ingestion, the esophagus rapidly propels food into the stomach through peristaltic contractions lasting only a few seconds. The most common pathologies associated with this region are gastroesophageal reflux disease, achalasia, eosinophilic esophagitis, esophageal cancer, esophageal spasms, and esophageal strictures, the symptoms of which include tissue irritation, inflammation, swelling, and muscle spasms, resulting in the reduction of the esophagus diameter. These disorders are typically assessed with the use of traditional endoscopes and capsules.

Once in the stomach, mechanical mixing and gastric secretions convert food into chyme. Residence times in the gastric region typically range from tens of minutes to several hours. Some of the most prevalent conditions include peptic ulcers, gastritis, and stomach cancer. Biomarkers such as pH, metabolites, enzymes, gases, electrolytes, bacteria, and overall integrity of the mucosa layer are essential parameters of a healthy stomach that can be monitored through traditional/capsule endoscopy, tissue biopsy, and gastric fluid sampling.

The small intestine is the principal site of digestion and absorption. In the duodenum, chyme is mixed with pancreatic enzymes and bile acids and then it is neutralized by bicarbonate secretions. The jejunum presents a large amount of villi and microvilli that greatly expand its absorptive surface and take up most nutrients. The terminal ileum absorbs bile acids, vitamin B12, and remaining nutrient fragments. Traditional endoscopy, colonoscopy, and capsule endoscopy are the most widely used methods to check for the well-being of the small intestine environment. An abnormality that mainly affects the small intestine is obstruction, which is a mechanical blockage of the bowel that hernias or intra-abdominal adhesions may cause. A complete bowel obstruction requires immediate surgery and accounts for 20% of all emergency surgical procedures.

The large intestine, comprising the cecum, colon, rectum, and anal canal, reabsorbs water and electrolytes and compacts waste into feces. Its dense microbial community plays an essential role in metabolism and immune modulation. Colonoscopy is the gold standard in assessing the quality of the colon mucosa, which may be compromised by inflammation and wounds. These are typically associated with a variety of disorders such as colorectal cancer, colonic polyps, and ulcerative colitis. Another powerful tool proves to be stool sample analysis, which may reveal abnormalities such as poor nutrient absorption and infections.

At the core of all of these processes lies the enteric nervous system (ENS), an extensive intrinsic neural network embedded in the submucosal and myenteric plexuses, which coordinates motility, secretion, local blood flow, and mucosal immune responses. It integrates mechanical, chemical, and hormonal cues to generate patterned motor activity throughout the GI tract, enabling autonomous regulation of digestion even in

the absence of CNS input. For gastrointestinal implants, the ENS is of particular importance, as it provides both a rich source of physiological signals and a therapeutic target for neuromodulation.

B. Signals

Understanding the GI tract therefore requires access to a variety of physical and biochemical cues that shape its activity. These cues are imprinted directly into the gut environment and can be captured by suitably designed devices.

A wide spectrum of physiological processes within the gastrointestinal tract gives rise to measurable signals that collectively reflect the state of motility, secretion, microbial activity, and neurochemical regulation. Mechanical cues, such as intraluminal pressure fluctuations and deformations of the gut wall, directly encode the patterned contractions orchestrated by the ENS and thus serve as sensitive indicators of transit dynamics, dysmotility, or obstruction. Superimposed on this mechanical landscape are chemical gradients, including pH, electrolytes, metabolites, and digestive enzymes, that track gastric acidity, nutrient breakdown, and mucosal health, providing essential biomarkers for conditions ranging from peptic ulcer disease to malabsorption and inflammatory bowel disorders. The gut's metabolic and microbial activity further produces distinctive gaseous signatures, notably oxygen, hydrogen, and carbon dioxide, whose local concentrations reveal fermentation patterns, oxygen tension, and regional transit; ingestible devices equipped with metal-oxide or thermal-conductivity sensors can capture these variations directly in situ. At a finer molecular scale, biological signals such as bacterial abundance, microbiome-derived metabolites, and neurotransmitters report on host-microbe interactions, immune activation, and the chemical messengers used by the ENS itself, enabling targeted probing of inflammatory or neurogastroenterological pathways. In parallel, the electrical properties of the local environment, ranging from temperature-dependent conductivity to semiconducting-gas sensor responses and direct measurements of core body temperature, provide an additional modality for tracking systemic physiology and identifying localized inflammation or tissue stress.

Together, these intertwined mechanical, chemical, gaseous, biological and electrical signals constitute the core modalities through which gastrointestinal implants can interrogate gut function, detect pathology and ultimately interface with the enteric nervous system.

C. Electronics

To sense, monitor and diagnose the native physiology of the gastrointestinal tract, a wide range of ingestible and implantable devices has emerged. These systems span simple, single-sensor capsules that measure parameters such as pH, temperature or pressure to more advanced platforms integrating optical, electrochemical or biological sensors for real-time biochemical analysis, camera-based endoscopic capsules for mucosal imaging, and therapeutic devices capable of targeted drug delivery, electrical or ultrasonic stimulation, or microbiota sampling. Architectures may incorporate wireless communication, localization modules or energy-harvesting components to extend autonomy and functionality.

This variety of device classes illustrates the rapidly expanding design space for gastrointestinal electronics, of which we will examine specific implementations in the following sections.

II. Ingestible Electronic Pills [1], [2]

Ingestible electronic pills represent a groundbreaking frontier in digital health, offering a safe, noninvasive way to monitor and interact with the body from within. These tiny, sensor-equipped devices travel through the gastrointestinal tract, collecting real-time data on vital parameters such as pH, temperature, pressure, and biomarkers. Some can even deliver targeted therapeutics or trigger diagnostic actions at precise locations. By combining advanced electronics, wireless communication, and biocompatible design, ingestible pills enable earlier detection of disease, personalized treatment, and improved patient compliance. As the technology matures, it promises to transform medical diagnostics and usher in a new era of intelligent, patient-centered healthcare.

A. Integrated Circuit

Integrated circuit (IC) design for ingestible electronic pills requires carefully balancing performance, size and power. After selecting the necessary sensors and actuators, designers must incorporate analogue and mixed-signal circuitry to amplify, filter and digitize sensor outputs. Although off-the-shelf analogue front ends (AFEs) are available, they are often larger and more power-hungry than desired for ultra-miniaturized capsules. Pairing a low-power amplifier with a compact Analog to Digital Converter (ADC) can reduce consumption, but may still increase overall footprint compared with a single integrated AFE. Custom AFEs, while significantly smaller and more energy-efficient as shown by comparisons with commercial options like the NJU9101, require substantial time and cost to design and fabricate. Selecting the optimal strategy is therefore essential for high-performance ingestible devices.

B. Communication Module

The communication module is a critical component in ingestible electronic pills, enabling real-time, wireless data exchange without retrieving the capsule. The wireless transceiver (TRX), which typically represents the most power- and area-intensive block, includes an antenna, matching network, and transmitter/receiver circuits. RF communication remains the dominant approach, with band selection influenced by tissue attenuation, antenna size and data-rate requirements. Mid-range frequencies such as MedRadio and 433 MHz ISM are commonly chosen, offering a practical balance between signal loss, antenna dimensions and throughput, as demonstrated in commercial systems like PillCam and SmartPill. Designers can use off-the-shelf TRX chips or develop custom solutions that minimize power and area while maintaining stable frequency performance. Recent crystal-less TRX designs demonstrate milliwatt-level operation and adequate data rates for compact capsules.

Alternative communication approaches, including body channel communication, ultrasound, and magnetic coupling, offer reduced attenuation and power, though they require skin-contact patches. Ultimately, communication performance must be matched to application needs, as high-data-rate capsules demand different TRX specifications than low-rate biochemical sensors. (Fig. 2)



Fig. 2. a) Block diagram and transceiver circuits of sensor, b. Components used for sensing and communication

C. Power Module

The power module is a defining factor in the operational lifetime and overall size of an ingestible electronic pill. Key considerations include volumetric capacity, form factor and patient safety. Most capsules rely on onboard batteries for stable, predictable power delivery. Silver-oxide batteries are currently the only clinically approved option due to their reliability and reduced risk compared to lithium-ion cells, while solid-state, flexible and transient biodegradable batteries offer promising alternatives with improved safety but often lower capacity. Emerging concepts such as 3D-printed and gel-based micro-batteries further expand design possibilities. Energy harvesting using piezoelectric, triboelectric or galvanic mechanisms can supplement power, but their application is limited by inconsistent physiological conditions. Remote powering through acoustic or RF transfer provides another pathway, delivering microwatt- to milliwatt-level energy, though efficiency depends on tissue attenuation and safety constraints such as specific absorption rate limits. Together, these considerations guide optimal power module selection for ingestible devices. [1]

D. Packaging Considerations

Packaging is a critical aspect of ingestible electronic pill design, driven by FDA-identified risks related to biocompatibility, structural integrity, electrical safety and the potential for intestinal obstruction. Encapsulation materials must be non-toxic, mechanically robust and capable of withstanding the harsh gastrointestinal environment. Common coatings such as polydimethylsiloxane and polyether ether ketone provide durability and reliable sealing, while 3D-printed biocompatible resins offer customizable geometries. When chemical or gas sensing is required, isolated openings or semi-permeable membranes allow interaction with the GI environment without exposing electronics. Capsule size and shape must also be carefully controlled, as larger pills increase retention risk. To mitigate this, designers increasingly explore smaller form factors and biodegradable components that safely disintegrate if retention occurs. [2]

E. Further Considerations

Beyond sensing, communication and power, ingestible pills also require reliable localization and locomotion. Localization is key for interpreting data and guiding wireless power, using methods ranging from imaging and physiological markers to RF, ultrasound, and magnetic techniques, with magnetic mapping offering sub-millimetre accuracy. Locomotion is typically passive through peristalsis; active mechanical or electrical propulsion is possible but power-intensive and raises safety concerns. Magnetic steering using external magnets offers precise, low-power control and has shown safe performance in clinical trials.

III. VBLOC and Gastric Pacemaker

Re-adapting proven technologies is a longstanding strategy in medicine, since established devices benefit from decades of refinement, safety data, and clinician familiarity. The cardiac pacemaker, now supported by more than 60 years of clinical experience, has shown itself to be a robust platform, finding use in multiple therapeutic technologies, including GI neuromodulation. Pacemakers are low-power electrical devices designed for full implantation within the body. Each device consists of a hermetically sealed metal housing that protects the battery, timing circuitry, and pulse generator. All of the pacemaker's function is controlled by an onboard logic control system which sets and supervises its performance. Electrical stimulation is delivered through insulated leads that extend from the housing to the target tissue [3]. For GI neuromodulation two common forms are Gastric Electrical Stimulation (GES) which applies electrical pulses to the stomach, and vagal nerve blocking (VBLOC) which targets the anterior and posterior vagal trunks (Fig. 3).



Fig. 3. Block diagram of a modern pulse generator [3]

A. Pulse Generator

Modern pacemaker pulse generators typically contain three core functional modules: the sense amplifier, the timing control, and the output driver [3]. The sense amplifier continuously monitors electrical activity via the implanted leads and relays an amplified signal to the control circuitry. This feedback loop is included on all modern pacemakers to enable closed

loop stimulation. The timing control determines the pulse duration and the repetition rate of the pulse generator based on instructions from the logic control and the sense feedback. Finally, the output driver shapes and delivers the electrical stimulus at the correct amplitude and duration through the leads to the tissue target [3].

B. Clinical Use

The two main uses for pacemaker-like neural-implants in the GI system are for gastroparesis and obesity. Gastroparesis is characterized by paralysis of the stomach which can lead to delayed emptying, nausea and vomiting. GI stimulation is used clinically in treating extreme cases of obesity when other methods have failed [4].

1) Gastroparesis: GES has been applied for more than two decades for upper GI muscle dysfunction [4]. Clinical benefits are strongest for nausea and vomiting control rather than for accelerating gastric emptying. Long term follow-ups over 15 years have demonstrated persisting symptom improvement in selected patients [4].

2) Obesity: VBLOC therapy targets vagal signaling to reduce hunger rather than directly modifying gastric motility or anatomy. By reducing the intensity and frequency of hunger signals, patients experience lower food intake [4], [5]. In the ReCharge Trial, 2 year follow-ups showed a mean excess weight loss of 21% and total weight loss of 8%, with accompanying improvements in LDL (16 mg/dL), triglycerides (46 mg/dL), and blood pressure [5]. Neuromodulation for obesity generally produces less weight loss than sleeve gastrectomy or gastric bypass, but with fewer major surgical risks such as leaks, ulcers, or nutritional deficiencies.

C. Placement and Manufactures

Interventions involving GES are invasive, involving surgeries for implantation either temporarily (endoscopic or percutaneous) or permanently (laparoscopic). Often a temporary mucosal or percutaneous implant is tested before a permanent implant is implemented. Endoscopic procedures are less invasive procedures than percutaneous or laparoscopic implants but are prone to lead dislodgement [4].

Permanent GES leads are typically placed laparoscopically on the gastric serosa, connected to a subcutaneously implanted neurostimulator. The Enterra system (Medtronic), a high-frequency, low-energy stimulator, is currently the most widely used commercial GES device for drug-refractory gastroparesis [4].

VBLOC systems, by contrast, position cuff-like electrodes around the vagal trunks near the gastroesophageal junction. The Maestro Rechargeable System (also known as vBloc therapy) was evaluated in multiple controlled trials and uses laparoscopic implantation on the thoracic abdominal wall [5].

D. Stimulation Outcomes

Electrical stimulation in the upper GI tract can be categorized into two main strategies depending on whether the target is symptom modulation or motility. GES for gastroparesis relies on high-frequency, low-energy pulses, while gastric pacing uses lower frequencies and longer pulses that align with the stomach's natural rhythm [4]. In obesity therapy, VBLOC uses high-frequency nerve blockade delivered intermittently across the day [5].

1) Gastric Electric Stimulation: In high-frequency / low-energy GES pulses are applied well above the native gastric slow wave rate with a pulse width of $\leq$ 0.6 ms. The Enterra system delivers constant-current pulses within the 5-7 mA range during. This approach has demonstrated symptom reduction in patients with drug resistant gastroparesis, with successful responders followed for more than 15 years. Because this mode does not aim to cause contractions, its primary therapeutic target is symptom control, particularly nausea and vomiting frequency [4].

For low-frequency / high-energy gastric pacing the goal is to restore physiologic slow-wave activity and strengthen contractions. Stimulation is delivered at approximately 3 cycles per minute using pulse widths $\geq$ 2 ms, which experimental and preclinical data has shown is required to modulate gastric motor activity meaningfully [4].

2) VBLOC: VBLOC therapy as the name suggests blocks vagal afferent signals between the stomach and brain that drive hunger perception. high-frequency intermittent stimulation is delivered for approximately 12–13 hours per day at a current amplitude of 6 mA. Two-year results demonstrated a 21% excess weight loss and accompanying improvements in lipid profile, blood pressure, and glycemic control. However, this approach has faced some criticism: by blocking vagal signaling rather than modulating it, VBLOC may also impair the transmission of normal satiety cues. In theory, this could limit the therapy's effectiveness by reducing the sensation of fullness at the same time it aims to suppress hunger [5].

IV. Conclusion

Gastrointestinal implants are a rapidly expanding set of technologies for both diagnosing and treating complex disorders of the digestive system. Ingestible electronic platforms now enable minimally invasive monitoring of chemical, mechanical, and biological signals throughout the gut, while advances in wireless communication, low-power integrated circuits, and biocompatible packaging continue to improve safety and usability. At the same time, implantable neuromodulation devices, adapted from decades of pacemaker development, provide meaningful symptom relief in severe gastric motility disorders and offer a reversible option for obesity management. Each approach addresses limitations in pharmacological therapy, particularly where patient response is inconsistent or surgical interventions carry high morbidity. Progress will depend on tighter sensing–stimulation integration, improved targeting of enteric neural pathways, and further miniaturization. Together, these technologies point toward more precise and adaptive GI disease management, improving real-time monitoring and modulation of gut function.

REFERENCES

[1] A. Abdigazy, M. Arfan, G. Lazzi, C. Sideris, A. Abramson, and Y. Khan, "End-to-end design of ingestible electronics," *Nature Electronics*, vol. 7, no. 2, pp. 102–118, 2024.

[2] G. Cummins, "Smart pills for gastrointestinal diagnostics and therapy," *Advanced Drug Delivery Reviews*, vol. 177, p. 113931, Oct. 2021, doi: 10.1016/j.addr.2021.113931.

[3] S. A. P. Haddad and W. A. Serdijn, "The Evolution of Pacemakers: An Electronics Perspective," in *Ultra Low-Power Biomedical Signal Processing*, Analog Circuits and Signal Processing series, Springer, Dordrecht, 2009, pp. 13–31. doi: 10.1007/978-1-4020-9073-8_2.

[4] Abell, Thomas L. and Chen, Jiande and Emmanuel, Anton and Jolley, Christopher and Sarela, Abeezar I. and Törnblom, Hans, "Neurostimulation of the gastrointestinal tract: Review of recent developments," *Neuromodulation: Technology at the Neural Interface*, no. 3, Apr. 2015, doi: 10.1111/ner.12260

[5] C. M. Apovian, S. N. Shah, B. M. Wolfe, S. Ikramuddin, C. J. Miller, K. S. Tweden, C. J. Billington, and S. A. Shikora, "Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge Trial," *Obesity Surgery*, vol. 27, no. 1, pp. 169–176, 2017. Published online Aug. 10, 2016. doi: 10.1007/s11695-016-2325-7.